Home LiteratureArticle Details
PMID: 11115698 Published · ppublish English Clinical Trial Clinical Trial, Phase I Controlled Clinical Trial Journal Article

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.

Vaccine ·Vol. 19 ·No. 7-8 ·2000-11-22 ·Pages 764-78

Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, Heydenburg Fuller D

Abstract

A DNA vaccine against the hepatitis B virus (HBV) was evaluated for safety and induction of immune responses in 12 healthy, hepatitis-naïve human volunteers using the needle-free PowderJect system to deliver gold particles coated with DNA directly into cells of the skin. Three groups of four volunteers received three administrations of DNA encoding the surface antigen of HBV at one of the three dose levels (1, 2, or 4 microg). The vaccine was safe and well tolerated, causing only transient and mild to moderate responses at the site of administration. HBV-specific antibody and both CD4+ and CD8+ T cell responses were measured before and after each immunization. All the volunteers developed protective antibody responses of at least 10 mIU/ml. In volunteers who were positive for the HLA class I A2 allele, the vaccine also induced antigen-specific CD8+ T cells that bound HLA-A2/HBsAg(335-343) tetramers, secreted IFN-gamma, and lysed target cells presenting a hepatitis B surface antigen (HBsAg) CTL epitope. Enumeration of HBsAg-specific T cells producing cytokine indicated preferential induction of a Type 1 T helper cell response. These results provide the first demonstration of a DNA vaccine inducing protective antibody titers and both humoral and cell-mediated immune responses in humans.

MeSH Terms
Adult Biolistics CD8-Positive T-Lymphocytes/immunology Female Gold Hepatitis B/immunology,prevention & control Hepatitis B Antibodies/biosynthesis Hepatitis B Surface Antigens/immunology Hepatitis B Vaccines/administration & dosage,adverse effects Hepatitis B virus/genetics,immunology Humans Male Middle Aged Particle Size Plasmids/genetics Safety T-Lymphocytes, Helper-Inducer/immunology Vaccines, DNA/administration & dosage,adverse effects
Chemicals
Hepatitis B Antibodies Hepatitis B Surface Antigens Hepatitis B Vaccines Vaccines, DNA Gold
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Roy M J
PowderJect Vaccines Inc., 585 Science Drive, Madison, WI 53711, USA.
Wu M S
Barr L J
Fuller J T
Tussey L G
Speller S
Culp J
Burkholder J K
Swain W F
Dixon R M
Widera G
Vessey R
King A
Ogg G
Gallimore A
Haynes J R
Heydenburg Fuller D
Article Info
Journal
Vaccine
Abbr.
Vaccine
ISSN
0264-410X
Published
2000-11-22
Pages
764-78
Language
English
Region
Netherlands
NLM ID
8406899
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com